Aspirin targets SIRT1 and AMPK to induce senescence of colorectal carcinoma cells

Molecular Pharmacology

Volumn 88, Issue 4, 2015, Pages 708-719

  Jung, Yu Ri ^a   Kim, Eun Ju ^a   Choi, Hyeong Jwa ^a   Park, Jung Jin ^b   Kim, Hak Su ^c   Lee, Yoon Jin ^a   Park, Myung Jin ^a   Lee, Minyoung ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; DORSOMORPHIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RESVERATROL; SELISISTAT; SIRTUIN 1; SMALL INTERFERING RNA; SIRT1 PROTEIN, HUMAN;

ARTICLE; CELL METABOLISM; COLON MUCOSA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EPITHELIUM CELL; HCT116 CELL LINE; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; PRIORITY JOURNAL; SENESCENCE; TREATMENT DURATION; CELL AGING; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES;

AMP-ACTIVATED PROTEIN KINASES; ASPIRIN; CELL AGING; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HCT116 CELLS; HUMANS; SIRTUIN 1;

EID: 84946761872     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.098616     Document Type: Article

References (81)

1. Alfonso L, Ai G, Spitale RC, and Bhat GJ (2014) Molecular targets of aspirin and cancer prevention. Br J Cancer 111:61-67.
2. Baur JA (2010) Biochemical effects of SIRT1 activators. Biochim Biophys Acta 1804: 1626-1634.
3. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, and Dai Y (2010) Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 6:599-612.
4. Cairney CJ, Bilsland AE, Evans TR, Roffey J, Bennett DC, Narita M, Torrance CJ, and Keith WN (2012) Cancer cell senescence: a new frontier in drug development. Drug Discov Today 17:269-276.
5. Campbell CL, Smyth S, Montalescot G, and Steinhubl SR (2007) Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297:2018-2024.
6. Cantó C and Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20:98-105.
7. Cantó C and Auwerx J (2012) Targeting sirtuin 1 to improve metabolism: all you need is NAD(1)? Pharmacol Rev 64:166-187.
8. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, and Auwerx J (2009) AMPK regulates energy expenditure by modulating NAD1 metabolism and SIRT1 activity. Nature 458:1056-1060.
9. Cantó C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, Zierath JR, and Auwerx J (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11:213-219.
10. Chan AT, Ogino S, and Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142.
11. Chan AT, Ogino S, and Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-658.
12. Chen X, Sun K, Jiao S, Cai N, Zhao X, Zou H, Xie Y, Wang Z, Zhong M, and Wei L (2014) High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients. Sci Rep 4:7481.
13. Coppé JP, Desprez PY, Krtolica A, and Campisi J (2010) The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu Rev Pathol 5: 99-118.
14. Currie E, Schulze A, Zechner R, Walther TC, and Farese RV Jr (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18:153-161.
15. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, and La Vecchia C et al. (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47-57.
16. Dasgupta B and Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104:7217-7222.
17. Davalos AR, Coppe JP, Campisi J, and Desprez PY (2010) Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 29:273-283.
18. Day RO, Graham GG, Bieri D, Brown M, Cairns D, Harris G, Hounsell J, Platt- Hepworth S, Reeve R, and Sambrook PN et al. (1989) Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 28:695-702.
19. Daye D and Wellen KE (2012) Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23:362-369.
20. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, and Toussaint O (2009) Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4:1798-1806.
21. Deng Y, Chan SS, and Chang S (2008) Telomere dysfunction and tumour suppression: The senescence connection. Nat Rev Cancer 8:450-458.
22. Din FV, Dunlop MG, and Stark LA (2004) Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 91:381-388.
23. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, and Dunlop MG (2012) Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142: 1504-1515.
24. Ewald JA, Desotelle JA, Wilding G, and Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102:1536-1546.
25. Gaidhu MP, Fediuc S, and Ceddia RB (2006) 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside-induced AMP-activated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake, lipid synthesis, and fatty acid oxidation in isolated rat adipocytes. J Biol Chem 281:25956-25964.
26. Grahame Hardie D (2014) AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med 276:543-559.
27. Hardie DG (2008) AMPK: A key regulator of energy balance in the single cell and the whole organism. Int J Obes 32 (Suppl 4):S7-S12.
28. Hardie DG (2013) AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62:2164-2172.
29. Hardie DG and Alessi DR (2013) LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol 11:36.
30. Hardwick JC, van Santen M, van den Brink GR, van Deventer SJ, and Peppelenbosch MP (2004) DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis 25:1293-1298.
31. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, and Mustard KJ et al. (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336:918-922.
32. Hennekens CH and Dalen JE (2013) Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med 126:373-378.
33. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, and Verbeuren TJ et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283:20015-20026.
34. Huang J, Gan Q, Han L, Li J, Zhang H, Sun Y, Zhang Z, and Tong T (2008) SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS One 3:e1710.
35. Huls G, Koornstra JJ, and Kleibeuker JH (2003) Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362:230-232.
36. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, and Shulman GI (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326.
37. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, and Stankunas K et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968.
38. Jin Q, Yan T, Ge X, Sun C, Shi X, and Zhai Q (2007) Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 213:88-97.
39. Jung-Hynes B and Ahmad N (2009) Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 8:1478-1483.
40. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, and Chen J (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 284:18210-18217.
41. Kamble P, Litvinov D, Aluganti Narasimhulu C, Jiang X, and Parthasarathy S (2015) Aspirin may influence cellular energy status. Eur J Pharmacol 749:12-19.
42. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, and Potapova A et al. (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479:547-551.
43. Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13:472-482.
44. Kumazaki M, Noguchi S, Yasui Y, Iwasaki J, Shinohara H, Yamada N, and Akao Y (2013) Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells. J Nutr Biochem 24:1849-1858.
45. Lanas A and Gargallo CJ (2015) Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol 50:626-637.
46. Lee M and Lee JS (2014) Exploiting tumor cell senescence in anticancer therapy. BMB Rep 47:51-59.
47. Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J, and Wu Y (2014) Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut [published ahead of print].
48. Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, Boilève A, Obrist F, Bordenave C, and Garcia P et al. (2014) Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proc Natl Acad Sci USA 111: 3020-3025.
49. Liu Q, Chan ST, and Mahendran R (2003) Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 24: 637-642.
50. Liu T, Liu PY, and Marshall GM (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69:1702-1705.
51. Mendonça FM, de Sousa FR, Barbosa AL, Martins SC, Araújo RL, Soares R, and Abreu C (2015) Metabolic syndrome and risk of cancer: which link? Metabolism 64:182-189.
52. Meng C, Wu S, and Xing D (2011) Real-time fluorescence imaging of SIRT1 cytosolic translocation under the treatment of growth factor deprivation. J Innov Opt Health Sci 4:133-141.
53. Michishita E, Park JY, Burneskis JM, Barrett JC, and Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16:4623-4635.
54. Motoshima H, Goldstein BJ, Igata M, and Araki E (2006) AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63-71.
55. O'Neill S and O'Driscoll L (2015) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16:1-12.
56. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y, and Kaneki M (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25:176-185.
57. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, and Ouchi Y (2007) Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 43:571-579.
58. Park JJ, Seo SM, Kim EJ, Lee YJ, Ko YG, Ha J, and Lee M (2012) Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin b1 signaling. BiochemBiophys Res Commun 426:461-467.
59. Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, and Lam EW (2010) SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9:844-855.
60. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, and Teodoro JS et al. (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675-690.
61. Rao CV and Reddy BS (2004) NSAIDs and chemoprevention. Curr Cancer Drug Targets 4:29-42.
62. Rodier F and Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192: 547-556.
63. Sade A, Tunçay S, Cimen I, Severcan F, and Banerjee S (2012) Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. Biosci Rep 32:35-44.
64. Sagiv A and Krizhanovsky V (2013) Immunosurveillance of senescent cells: The bright side of the senescence program. Biogerontology 14:617-628.
65. Sebastián C, Satterstrom FK, Haigis MC, and Mostoslavsky R (2012) From sirtuin biology to human diseases: an update. J Biol Chem 287:42444-42452.
66. Seedher N and Bhatia S (2003) Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 4:E33.
67. Shin SM, Cho IJ, and Kim SG (2009) Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol 76:884-895.
68. Sostres C and Gargallo CJ (2012) Gastrointestinal lesions and complications of lowdose aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 26: 141-151.
69. Sostres C, Gargallo CJ, and Lanas A (2013) Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 15 (Suppl 3):S3.
70. Steinberg GR, Dandapani M, and Hardie DG (2013) AMPK: mediating the metabolic effects of salicylate-based drugs? Trends Endocrinol Metab 24:481-487.
71. Suzuki M and Boothman DA (2008) Stress-induced premature senescence (SIPS)- influence of SIPS on radiotherapy. J Radiat Res (Tokyo) 49:105-112.
72. Tanno M, Sakamoto J, Miura T, Shimamoto K, and Horio Y (2007) Nucleocytoplasmic shuttling of the NAD1-dependent histone deacetylase SIRT1. J Biol Chem 282: 6823-6832.
73. Tchkonia T, Zhu Y, van Deursen J, Campisi J, and Kirkland JL (2013) Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 123:966-972.
74. Thun MJ, Henley SJ, and Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266.
75. Usman MW, Luo F, Cheng H, Zhao JJ, and Liu P (2015) Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta 1855:254-263.
76. Vander Heiden MG, Cantley LC, and Thompson CB (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
77. Vucenik I and Stains JP (2012) Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci 1271:37-43.
78. Wang Y, Liang Y, and Vanhoutte PM (2011) SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett 585:986-994.
79. Ye XF, Wang J, Shi WT, and He J (2014) Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br J Cancer 111:2172-2179.
80. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, and Fujii N et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174.
81. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, and Jasser SA et al. (2014) Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 54:960-974.